Objective To evaluate the comprehensive effects of rosuvastatin combined with cardiac rehabilitation on lipid metabolism, cardiac function, inflammatory response, and quality of life in patients with coronary heart disease (CHD).

Methods CHD patients admitted to Huzhou First People's Hospital from January 2024 to August 2025 were selected and divided into an observation group (rosuvastatin + cardiac rehabilitation + conventional treatment) and a control group (rosuvastatin + conventional treatment) based on treatment protocols. Serum lipid profiles [TC, TG, LDL-C, HDL-C, and Lp(a)], cardiac function parameters (LVEF, LVEDD, SV, and E/A ratio), inflammatory markers (hs-CRP and NLR), myocardial injury biomarkers (cTnI and CK-MB), and quality of life scores (SF-36) were compared between the two groups before and after a 12-week intervention. Clinical efficacy and the incidence of adverse reactions were also recorded.

Results Before treatment, there were no significant differences in any parameters between the two groups (P>0.05). After 12 weeks of treatment,the total effective rate of treatment in the observation group was higher than that in the control group (94.87% vs. 79.22%, P<0.05). Furthermore, the levels of TC, TG, LDL-C, hs-CRP, NLR, cTnI, and LVEDD were all significantly reduced compared to baseline in both groups; however, only the levels of Lp(a) and CK-MB were significantly decreased in the observation group compared to baseline, while HDL-C, LVEF, SV, the E/A ratio, and SF-36 scores in all domains increased significantly (all P<0.05). Notably, the observation group showed significantly greater improvements in all aforementioned indicators compared to the control group (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (7.69% vs. 10.39%, P>0.05).

Conclusion Rosuvastatin combined with cardiac rehabilitation can multidimensionally improve lipid metabolism, cardiac function, inflammatory status, and quality of life in CHD patients while reducing the risk of myocardial injury. This model demonstrates significant clinical efficacy and favorable safety, warranting standardized promotion.

1. 张晏铭, 于高修, 王聪, 等. 早发冠心病发病机制与预防的研究进展[J]. 中国临床医学, 2024, 31(3): 491-498.ZhangYM, YuGX, WangC, et al. Research progress on pathogenesis and prevention of premature coronary heart disease[J]. Chinese Journal of Clinical Medicine, 2024, 31(3): 491-498. DOI: 10.12025/j.issn.1008-6358.2024.20231914.

2. YanaiH, AdachiH, HakoshimaM, et al. Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment[J]. Int J Mol Sci, 2022, 23(7): 3418. DOI: 10.3390/ijms23073418.

3. LiuJ, ZhaoQ, ShenQ, et al. Advances in theories and models of cardiac rehabilitation after acute myocardial infarction: a narrative review[J]. Medicine (Baltimore), 2024, 103(51): e39755. DOI: 10.1097/MD.0000000000039755.

4. 中华医学会心血管病学分会, 中国康复医学会心血管病专业委员会, 中国老年学学会心脑血管病专业委员会. 冠心病康复与二级预防中国专家共识[J]. 中华心血管病杂志, 2013, 41(4): 267-275.Chinese Society of Cardiology, Chinese Society of Rehabilitation Medicine-Cardiovascular Disease Professional Committee, Chinese Geriatrics Society-Cardiovascular and Cerebrovascular Diseases Professional Committee. Chinese expert consensus on rehabilitation and secondary prevention of coronary heart disease[J]. Chinese Journal of Cardiology, 2013, 41(4): 267-275. DOI: 10.3760/cma.j.issn.0253-3758.2013.04.003.

5. DibbenGO, FaulknerJ, OldridgeN, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis[J]. Eur Heart J, 2023, 44(6): 452-469. DOI: 10.1093/eurheartj/ehac747.

6. 中华医学会物理医学与康复学分会, 四川大学华西医院. 中国冠心病康复循证实践指南(2024版)第一部分[J]. 中华物理医学与康复杂志, 2024, 46(6): 481-491. DOI: 10.3760/cma.j.issn.0254-1424.2024.06.001.

7. 中华医学会物理医学与康复学分会, 四川大学华西医院. 中国冠心病康复循证实践指南(2024版)第二部分[J]. 中华物理医学与康复杂志, 2024, 46(7): 577-586. DOI: 10.3760/cma.j.issn.0254-1424.2024.07.001.

8. 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国慢性冠脉综合征患者诊断及管理指南[J]. 中华心血管病杂志, 2024, 52(6): 589-614.Chinese Society of Cardiology, Chinese Medical Association Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and management of patients with chronic coronary syndrome[J]. Chinese Journal of Cardiology, 2024, 52(6): 589-614. DOI: 10.3760/cma.j.cn112148-20240325-00168.

9. 中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9): 680-694.Section of Interventional Cardiology of Chinese Society of Cardiology, Section of Atherosclerosis and Coronary Artery Disease of Chinese Society of Cardiology, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, et al. Guideline on the diagnosis and treatment of stable coronary artery disease[J]. Chinese Journal of Cardiology, 2018, 46(9): 680-694. DOI: 10.3760/cma.j.issn.0253-3758.2018.09.004.

10. 国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南[J]. 中国医学前沿杂志(电子版), 2016, 8(6): 19-108. DOI: 10.3969/j.issn.1674-7372.2016.06.007.

11. 陈本福. 瑞舒伐他汀联合高强度间歇有氧运动对老年高脂血症合并冠心病患者心肺功能的影响[J]. 临床合理用药, 2024, 17(22): 44-47. DOI: 10.15887/j.cnki.13-1389/r.2024.22.012.

12. FranczykB, Gluba-BrzózkaA, Ciałkowska-RyszA, et al. The impact of aerobic exercise on hdl quantity and quality: a narrative review[J]. Int J Mol Sci, 2023, 24(5): 4653. DOI: 10.3390/ijms24054653.

13. MuscellaA, StefànoE, MarsiglianteS. The effects of exercise training on lipid metabolism and coronary heart disease[J]. Am J Physiol Heart Circ Physiol, 2020, 319(1): H76-H88. DOI: 10.1152/ajpheart.00708.2019.

14. 喻晓雨, 朱晓丹. 瑞舒伐他汀联合阶段性功能锻炼对老年冠心病患者的疗效及心功能水平的影响[J]. 老年医学与保健, 2024, 30(3): 787-792.YuXY, ZhuXD. Effects of rosuvastatin combined with periodic functional exercise on efficacy and cardiac function in elderly patients with coro-nary heart disease[J]. Geriatrics & Health Care, 2024, 30(3): 787-792. DOI: 10.3969/j.issn.1008-8296.2024.03.040.

15. HakimzadehN, VerberneHJ, SiebesM, et al. The future of collateral artery research[J]. Curr Cardiol Rev, 2014,10(1): 73-86. DOI: 10.2174/1573403x113099990001.

16. ZhangX, MiY, DingM, et al. Effects of exercise training on left ventricular systolic and diastolic function after myocardial infarction: systematic review and meta-analysis[J]. Front Cardiovasc Med, 2025, 12: 1526326. DOI: 10.3389/fcvm.2025.1526326.

17. Marcos-GarcésV, Bertolín-BoronatC, Merenciano-GonzálezH, et al. Left ventricular remodeling after myocardial infarction-pathophysiology, diagnostic approach and management during cardiac rehabilitation[J]. Int J Mol Sci, 2025, 26(22): 10964. DOI: 10.3390/ijms262210964.

18. Baffour-AwuahB, ManM, GoesslerKF, et al. Effect of exercise training on the renin-angiotensin-aldosterone system: a meta-analysis[J]. J Hum Hypertens, 2024, 38(2): 89-101. DOI: 10.1038/s41371-023-00872-4.

19. ZhuQ, WuY, MaiJ, et al. Comprehensive metabolic profiling of inflammation indicated key roles of glycerophospholipid and arginine metabolism in coronary artery disease[J]. Front Immunol, 2022, 13: 829425. DOI: 10.3389/fimmu.2022.829425.

20. HeJ, SongC, ZhangR, et al. Discordance between neutrophil to lymphocyte ratio and high sensitivity c-reactive protein to predict clinical events in patients with stable coronary artery disease: a large-scale cohort study[J]. J Inflamm Res, 2023, 16: 5439-5450. DOI: 10.2147/JIR.S428734.

21. FlynnMG, McFarlinBK, MarkofskiMM. The anti-inflammatory actions of exercise training[J]. Am J Lifestyle Med, 2007, 1(3): 220-235. DOI: 10.1177/1559827607300283.

22. KhalafiM, FatolahiS, FiniEM, et al. Comparative efficacy of different modes of exercise on inflammatory markers in patients with chronic kidney disease: a systematic review with pairwise and network meta-analyses[J]. Sci Rep, 2026, 16(1): 17312. DOI: 10.1038/s41598-026-45519-9.